Research That Speeds Advanced Treatments to Our Patients
Roswell Park places a strong emphasis on research that can bring the latest and most advanced treatments to our patients.
In June of 2019, the FDA approved a lymphoma treatment called polatuzumab vedotin (Polivy®), which originated in the laboratory of Ben Seon, PhD, Professor in the Department of Immunology at Roswell Park. It provides a treatment option for many patients with diffuse large B-cell lymphoma (DLBCL) who cannot be treated with other available drugs. Eligible Roswell Park patients had access to Polivy through clinical trials even before it was FDA-approved, and information generated by those trials led to the drug’s approval.
Experts Who Help Set the Standards
Members of our Lymphoma team are among the experts who serve on the National Comprehensive Cancer Network (NCCN) panels that write the national guidelines for the diagnosis and treatment of lymphomas. Francisco Hernandez-Ilizaliturri, MD, Chief of Lymphoma, is a member of both the Hodgkin Lymphoma and Non-Hodgkin Lymphoma panels. Pallawi Torka, MD, is a member of the T-Cell Lymphomas panel, and Suchitra Sundaram, MD, serves on the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma panel.
Fast, Early, Accurate Detection & Diagnosis
Roswell Park’s hematology (blood) pathologists concentrate on diagnosing blood cancers — nothing but blood cancers — every single day. They are part of a dedicated, highly skilled team of specialists who have extensive experience in identifying the many different subtypes of lymphoma.
Our Flow and Image Cytometry facility, recognized as one of the nation’s best, makes it possible to quickly identify your specific type of lymphoma — information that will help your medical team create the best treatment plan for you. In addition, our dedicated genetic and molecular laboratories process our samples quickly and efficiently to determine the best treatment approach as soon as possible — usually within a few days.